Effects of the mTOR and AKT genes polymorphisms on systemic lupus erythematosus risk.
Mohsen SaravaniHossein Shahraki-GhadimiRostam Maruei-MilanMehrnaz MehrabaniSolmaz MirzamohammadiMohammad Hadi NematollahiPublished in: Molecular biology reports (2020)
The systemic lupus erythematosus (SLE) is an autoimmune disease, leading to inflammatory response and systemic consequences. The mammalian target of rapamycin (mTOR) is a therapeutic target for autoimmune diseases like SLE. The aim of this study was to evaluate the effects of the mTOR rs2295080 and rs2536 polymorphisms and AKT1 rs2494732 gene polymorphism on SLE development. 2 ml of peripheral blood was collected from 165 SLE patients and 170 controls in EDTA-containing tubes. The salting-out and PCR-RFLP methods were used for DNA extraction and genotype analysis, respectively. Based on the regression analysis, the frequency of TT genotype of mTOR rs2295080 polymorphism was significantly higher in the case group than that of the control group, with a 2.6-fold increased risk of SLE. There was also a significant difference between the two groups in terms of allelic distribution. No statistically significant association was found between The AKT1 rs2494732 and mTOR rs2536 polymorphisms and SLE development. Our results showed that the TT genotype and T allele of mTOR rs2295080 polymorphism were risk factors for developing SLE. However, there was no significant association between mTOR rs2536 and AKT1 rs2494732 polymorphisms and the SLE risk.
Keyphrases
- systemic lupus erythematosus
- cell proliferation
- disease activity
- signaling pathway
- inflammatory response
- peripheral blood
- end stage renal disease
- multiple sclerosis
- gene expression
- chronic kidney disease
- rheumatoid arthritis
- ejection fraction
- newly diagnosed
- lipopolysaccharide induced
- prognostic factors
- cell free
- peritoneal dialysis
- circulating tumor
- transcription factor